To Evaluate SBI in the Dietary Management of Mild to Moderate Crohn's Disease

Inclusion Criteria: * Confirmed diagnosis of mild to moderate Crohn's disease for at least 3 months. * Screening CDAI between \>150 and ≤ 250 based on subject recall. * Average of greater than two liquid or soft stools per day and an abdominal pain intensity score \>1. * Subject has at least one positive biomarker of inflammation: fecal calprotectin \>100 µg/g; elevated C-reactive protein (CRP) \>2 mg/dL. Exclusion Criteria: * Positive stool test for pathogenic bacteria including Clostridium difficile or O\&P. * Confirmed intestinal stricture with obstructive-like clinical symptoms. * Bowel resection within the previous 6 months. * Change in medical therapy: must have been on a stable dose of * corticosteroids (prednisone or prednisolone) less than or equal to 20 mg per day for 2 weeks prior to screening, * budesonide less than or equal to 9 mg per day for 2 weeks prior to screening, * 5-aminosalicylates for 2 weeks prior to screening, and * immunomodulators for 6 weeks prior to screening. * Taking greater than 20 mg per day of a corticosteroid (prednisone or prednisolone) or greater than 9 mg of budesonide. * Received biologic therapy in past 2 years. * Diagnosis of one or more co-morbid condition (s) requiring medical or surgical therapy that may affect bowel function, gastrointestinal symptoms. * Serious infection in the 3 months prior to enrollment. * Allergy or intolerance to beef or to any ingredient used in the product. * Participated in an investigational drug or device study within 30 days. * Does not have access to the internet. * Taken EnteraGam®